The Russian market of medicines for the therapy of urogenital chlamydiasis
- Authors: Mukovnina M.D.1, Ovod A.I.2, Komissinskaya I.G.2
-
Affiliations:
- N.N. Burdenko Voronezh State Medical University
- Kursk State Medical University
- Issue: Vol 69, No 1 (2020)
- Pages: 33-39
- Section: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113282
- DOI: https://doi.org/10.29296/25419218-2020-01-06
- ID: 113282
Cite item
Open Access
Access granted
Abstract
Introduction. Due to the population's high demand for medical care for social diseases, the Russian market of medicines used to treat them was studied. Objective: to analyze the range of drugs for social diseases (for example, those to cure urogenital chlamydiasis). Material and methods. Patient management protocols, clinical guidelines for management, and official sources of information were applied. Logical, systematic analytical, graphical, marketing, and statistical (tabular, graphical) analyses were used. Results. The paper presents the results of analyzing the market of medicines for the treatment of social diseases, such as urogenital chlamydiasis, as of 2018. The investigators revealed the problems of the availability of drugs in ATC groups. The comparative analysis of the range of drugs in 2012 and 2018 showed no dramatic change in the pattern of their range. The number of trade names for the assortment under study increased 2.3-fold (primarily due to Russian manufacturers), which is suggestive of the development of the Russian pharmaceutical industry. Conclusion. The range of drugs for the treatment of urogenital chlamydiasis is under government control: many basic drugs for its therapy are included in the list of essential medicines; this provides government control of pricing and increases their availability for patients. However, there is some dependence on import for individual drugs.
Full Text
About the authors
Marina D. Mukovnina
N.N. Burdenko Voronezh State Medical University
Email: mukovninamarina@yandex.ru
Alla I. Ovod
Kursk State Medical University
Email: aovod@mail.ru
Irina G. Komissinskaya
Kursk State Medical University
Email: ikomissinska@mail.ru
References
- Володина Т.А., Саськова П.В., Иванова Е.В. Урогенитальный хламидиоз: современное состояние вопроса. Фармация и фармакология, 2014;2 (6-7):66-73. https://doi. org/10.19163/2307-9266-2014-2-6(7)-66-73
- Малова И.О., Сидорова И.А., Шеломенцева Н.Н. Урогенитальный хламидиоз у женщин репродуктивного возраста: рациональный подход к терапии. Сибирский медицинский журнал (Иркутск), 2013; 117(2): 46-50.
- Глобальная стратегия сектора здравоохранения по инфекциям, передаваемым половым путем 2016-2021 гг. ВОЗ; 2016. Электронное издание]. Режим доступа: http://www.who. int/mediacentre/factsheets/fs110/ru
- Patel C.G., Trivedi S., Tao G. The Proportion of Young Women Tested for Chlamydia Who Had Urogenital Symptoms in Physician Offices. Sex. Transm. Dis., 2018 Sep; 45 (9): e72-e74. https://doi.org/10.1097/0LQ.0000000000000858
- Кубанова А.А., Кубанов А.А, Мелехина Л.Е. Динамика изменений интенсивных показателей заболеваемости инфекций, передаваемым половым путем, в оценке эпидемиологического процесса и состояния здоровья населения Российской Федерации за 2006-2016 годы. Вестник дерматологии и венерологии, 2018; 94(1): 27-37. https://doi.org/10.25208/0042-4609-2018-94-1-27-37
- Hathorn E., Opie C., Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex. Transm. Infect., 2012; аug; 88(5): 352 4. https://doi.org/10.1136/sextrans-2011-050466
- Хрянин А.А. Урогенитальная хламидийная инфекция у женщин: тактика ведения пациенток в соответствии с современными зарубежными и российскими рекомендациями. Вестник дерматологии и венерологии, 2015; 2: 101-10. https:// doi.org/10.25208/0042-4609-2015-0-2-101-110
- Государственный реестр лекарственных средств Российской Федерации. [Электронное издание]. Режим доступа: https:// grls.rosminzdrav.ru/grls.aspx
Supplementary files
